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SUMMARY : Statistical and histopathological analysis was carried out to 
determine whether hepatitis B surface antigen with the necropsy diagnosis of hepati-
tis, cirrhosis, and hepatocellular carcinoma declined during 1964-1984. In this study, 
the liver specimens from 500 necropsy cases at Nagasaki University Hospital were 
used, and these materials were stained for hepatitis B surface antigen with immuno-
peroxidase method. For statistical calculations, we used Cochran's chi-squared test 
with one degree of freedom for linear trend for proportions. We investigated hepati-
tis B surface antigen positive rates for the three times periods, 1964-1970, 1971-1977, 
and 1978-1984, and those in the three diagnosis of hepatitis, cirrhosis, and hepatocell-
ular carcinoma. The decreasing linear trend of hepatitis B surface antigen positivity 
with time was significant for hepatocellular carcinoma (and also for all three 
diagnosis combined ). This suggests that infection by hepatitis B virus in blood 
transfusion had fallen over the period in question.
       INTRODUCTION 
 Hepatocellular carcinoma becomes clinically 
manifest after cirrhosis has been well formed, 
and the major factor predisposing hepatocellu-
lar carcinoma in a population appears to be 
the presence of cirrhosis caused by chronic 
hepatitis B virus infection in that population. 
The oncogenic potential of hepatitis B virus in 
the development of hepatocellular carcinoma 
has been reported .7-10) The landmark discovery 
of the hepatitis B surface antigen and the link-
ing of this antigen to viral hepatitis provided 
the cornerstone for the rapid acceleration of 
our understanding of viral hepatitis in general, 
and posttransfusion hepatitis in particular. 1,2)
Hepatitis B surface antigen was widely assum-
ed that development of efficient screening tests 
would detect type B hepatitis infection carriers 
and make possible the eradication of the pro-
blem of posttransfusion type B hepatitis by 
preventing transfusion of hepatitis B virus 
positive blood. Therefore, the objective of this 
study is to know whether hepatitis B surface 
antigen positive rates in hepatitis, cirrhosis, 
and hepatocellular carcinoma have changed or 
not during 1964-1984.
   MATERIALS AND METHODS 
 The liver epecimens were collected at 
Nagasaki University Hospital from 500 necro-
psy cases of various liver diseases, including
hepatitis (52 cases), cirrhosis (177 cases), and 
hepatocellular carcinoma (271 cases). The 
materials were fixed in formalin, and embedded 
in paraffin for histochemical and immunohisto-
chemical study. Sections were cut at 4 micron, 
and stained with hematoxylin-and-eosin, 
Mallory's method for collagen fibers, and 
silver impregnation method for reticulum fibers. 
For immunohistochemical study, these speci-
mens were stained with hepatitis B surface 
antigen (Dako PAP Kit) by immunoperoxidase 
method. Statistical calculation was performed 
using the BMDP 3 ) on the IBM 4341 system in 
the Data Center of A-bomb Disaster in 
Nagasaki University. The statistical method 
for this study is the Cochran's chi-square test 
with one degree of freedom for trend of propor-
tions.
          RESULTS 
 Table 1 shows hepatitis B surface antigen 
positive results obtained by immunoperoxidase
procedure (Figs. 1-3). Of the 18 hepatitis cases 
in 1964-1970, of the 16 in 1971-1977, and of the 
18 in 1978-1984, 3 (17%), 2 (13%), and 2 (11%) 
were hepatitis B surface antigen positive, 
respectively. As for the cirrhosis cases, 23 (34 
% ) cases were hepatitis B surface antigen 
positive out of 67 in 1964-1970, 15 (28%) out 
of 53 in 1971-1977, and 12 (21%) out of 57 in 
1978-1984. Of the 87, 102, and 82 hepatocellular 
carcinoma cases in 1964-1970, 1971-1977, and 
1978-1984, 56 (64%), 57 (56%), and 37 (45%) 
were hepatitis B surface antigen positive, 
respectively. Results of the statistical 
analysis on the positive rates of hepatitis B 
surface antigen, in hepatitis, cirrhosis, and 
hepatocellular carcinoma are as follows : The 
Cochran's chi-square test for the linear trend 
of hepatitis B surface antigen positive rate in 
hepatitis during the periods resulted in x 2 = 
0.238 (p>0.50), that in cirrhosis x2 =2.671 (p 
<0.10), that in hepatocellular carcinoma x2 = 
6.312 (p<0.01), and that in total of these 
diseases x2 =7.710 (p<0.01).
Table 1. Long-term trend of decreasing frequency of hepatitis B virus 
        infction in hepatitis, cirrhosis, and hepatocellular carcinoma
                    1964-1970 1971-1977 1978-1984 
Hepatitis 3/ 1807%) 2/ 16(13%) 2/ 1801%) 
Cirrhosis 23/ 67(34%) 15/ 53(28%) 12/ 57(21%) 
Hepatocellular 56/ 87(64%) 57/102 (56%) 37/ 82 (45%) 
carcinoma 
Total 82/172 (48%) 74/171 (43%) 51/157 (32%)
Fig. 1. Inclusion type of hepatitis B surface 
       antigen are seen in the hepatocytes. 
      Immunoperoxidase method for hepatitis 
      B surface antigen ( x400).
Fig. 2. Peripheral type of hepatitis B surface 
       antigen are seen in the hepatocytes. 
      Immunoperoxidase method for hepatitis 
      B surface antigen (X400).
Fig. 3. Membrane type and inclusion type of 
       hepatitis B surface antigen are seen in
       the hepatocytes. Immunoperoxidase 
       method for hepatitis B surface antigen 
     ( X400).
        DISCUSSION 
 Hepatocellular carcinoma becomes clinically 
manifest after cirrhosis is well advanced, and 
the major factor predisposing to hepatocellu-
lar carcinoma in a population seems to be 
cirrhosis due to chronic hepatitis B virus infect-
ion. It has been widely assumed that the 
development of efficient screening test for 
hepatitis B surface antigen would detect type 
B hepatitis infection carriers and make 
possible the eradication of posttranfusion 
hepatitis B. The decreasing trend of hepatitis 
B surface antigen positive rates in hepatocellu-
lar carcinoma during 1964-1984 was highly 
significant (p<0.01), but marginally signifi-
cant (p<0.10) in cirrhosis, and was highly 
significant (p<0.01) in total. Therefore, in 
this study, proportions of hepatitis B surface 
antigen carrier in cirrhosis and hepatocellular 
carcinoma in the last 21 years were found to 
have been decreasing. The decrease trend of 
hepatitis B surface antigen positive rates might 
suggest that infection of type B virus caused 
by posttransfusion was more prevented in the 
latter period. 
 Widespread application of serologic tests for 
hepatitis B surface antigen has underscored the 
significance of hepatitis B as a clinical and 
public health problem. Hepatitis B surface 
antigen in the blood of a patient or of an
apparently healthy person raises quetions not 
only of the presence of liver disease but also 
of the risk of transmitting infection to others. 
The likelihood of transmitting hepatitis B 
virus to susceptible contacts is related to 
many factors including personal and environ-
mental hygiene, public education, and the safety 
of blood transfusion. They have been partially 
sucessful.6) Furthermore, definitive control or 
prevention of hepatitis B awaits development 
of biologic for active and passive immuniz-
ation or other specific measures. Specifically, 
intervention with hepatitis B vaccine may lead 
to a reduction in the incidence of hepatitis, 
cirrhosis, and hepatocellular carcinoma caused 
by hepatitis B virus infection.
         ADDENDUM 
 The summary of this investigation was 
published in the March 12, 1988 issue of the 
Lancet.
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